1. Aspergillus spondylodiscitis successfully treated with a long course of isavuconazole.
- Author
-
Teigell Muñoz FJ, Sánchez-de Torre A, Jiménez-Fernández M, Zuñiga Gómez L, Mateos-González M, Batiray Polat A, and Fortún Abete J
- Subjects
- Humans, Male, Voriconazole therapeutic use, Treatment Outcome, Aged, Middle Aged, Nitriles therapeutic use, Pyridines therapeutic use, Triazoles therapeutic use, Antifungal Agents therapeutic use, Aspergillosis drug therapy, Aspergillosis microbiology, Discitis drug therapy, Discitis microbiology, Aspergillus fumigatus drug effects, Aspergillus fumigatus isolation & purification
- Abstract
We present a case of spondylodiscitis caused by Aspergillus fumigatus, which we successfully treated with isavuconazole after voriconazole severe intolerance. Aspergillus spondylodiscitis is a severe and relatively rare form of extra-pulmonary invasive aspergillosis. Typically, voriconazole is the first-choice antifungal drug for treating Aspergillus osteomyelitis or spondylodiscitis. However, isavuconazole, a new antifungal medication, has been demonstrated as non-inferior to voriconazole in cases of invasive aspergillosis. It has the added benefits of fewer hepatobiliary, ocular, and cutaneous side effects. It generally does not demand serum level monitoring and poses fewer risks of drug interactions. Nonetheless, there are no studies yet that support its use in spondylodiscitis, and published experiences are very limited and based on isolated cases, albeit mainly positive. The case we present here aims to provide additional evidence on the efficacy and tolerability of isavuconazole in treating this condition., Competing Interests: Declaration of competing interest JF was an advisor/consultant and received grant support and honoraria for talks on behalf of Astellas Pharma, Gilead Sciences, Merck Sharp & Dohme, Shionogi, Mundipharma and Pfizer., (Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF